Month: December 2023

Zydus Cadila launches anti-ulcer drug in US. NEW DELHI: Zydus Cadila has launched mesalamine delayed release tablets, used for the treatment of ulcerative colitis, in the US market. “Zydus CadilaBSE -1.00 % has commercially launched its mesalamine delayed release tablets in the US market. ZydusBSE 0.68 % was the first to file an Abbreviated New… Continue reading Zydus Cadila launches anti-ulcer drug in US.

To fight China monopoly, Indian Govt to approve for 4 mega bulk drugs parks New Delhi: The Indian Government has decided to hasten the approvals for mega bulk drugs parks in the country to counter the China’s dominance in the sector. Bulk drugs, also known as active pharmaceutical ingredients (API), are the raw materials for the… Continue reading To fight China monopoly, Indian Govt to approve for 4 mega bulk drugs parks

The U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. The U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults.

The U.S. Food and Drug Administration issued a draft guidance which, once finalized, will assist cosmetics companies submitting cosmetic product facility registrations and cosmetic product listings, including ingredients, to the FDA. The U.S. Food and Drug Administration issued a draft guidance which, once finalized, will assist cosmetics companies submitting cosmetic product facility registrations and cosmetic… Continue reading The U.S. Food and Drug Administration issued a draft guidance which, once finalized, will assist cosmetics companies submitting cosmetic product facility registrations and cosmetic product listings, including ingredients, to the FDA.

The U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. The U.S. Food and Drug Administration approved Abrysvo (Respiratory… Continue reading The U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

The The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). The The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing… Continue reading The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).

Bimervax, the COVID-19 vaccine developed by HIPRA Bimervax, the COVID-19 vaccine developed by HIPRA Human Health, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

Bimervax, the COVID-19 vaccine developed by HIPRA Human Health, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax, the COVID-19 vaccine developed by HIPRA Human Health, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).